How Will the Market React to Lexicon Pharmaceuticals Inc (LXRX) Stock Getting a Bearish Rating

Overall market sentiment has been down on Lexicon Pharmaceuticals Inc (LXRX) stock lately. LXRX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Lexicon Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on LXRX!

See Full LXRX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LXRX Stock Today?

Lexicon Pharmaceuticals Inc (LXRX) stock is trading at $1.13 as of 1:08 PM on Wednesday, Nov 22, a rise of $0.04, or 4.17% from the previous closing price of $1.08. The stock has traded between $1.10 and $1.15 so far today. Volume today is light. So far 536,357 shares have traded compared to average volume of 2,852,248 shares. To see InvestorsObserver's Sentiment Score for Lexicon Pharmaceuticals Inc click here.

More About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Click Here to get the full Stock Report for Lexicon Pharmaceuticals Inc stock.